18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease

被引：23

作者：

Ansquer, Catherine ^{[1
]}

Hervouet, Thomas ^{[2
]}

Devillers, Anne ^{[2
]}

de Guibert, Sophie ^{[3
]}

Gastinne, Thomas ^{[4
]}

Le Gouill, Steven ^{[4
]}

Garin, Etienne ^{[2
]}

Moreau, Anne ^{[5
]}

Kraeber-Bodere, Francoise ^{[1
]}

Lamy, Thierry ^{[3
]}

机构：

[1] CHU Nantes, Dept Med Nucl, Nantes, France

[2] Ctr Eugene Marquis, Dept Med Nucl, Rennes, France

[3] CHU Rennes, Serv Hematol Clin, Hop Pontchaillou, F-35033 Rennes, France

[4] CHU Nantes, Serv Hematol Clin, Hop Hotel Dieu, Rennes, France

[5] CHU Nantes, Lab Anat Pathol, Hop Hotel Dieu, Rennes, France

来源：

HAEMATOLOGICA | 2007年 / 93卷 / 01期

关键词：

18F FDG-PET; FDG-PET/CT; lymphocyte-predominant Hodgkin's disease; staging;

D O I：

10.3324/haematol.11661

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This bicentric study assessed retrospectively the usefulness of 18 F-FDG-PET in the staging of 31 patients with lymphocyte-predominant Hodgkin's disease (LPHD). FDG-PET and conventional explorations (CE) were performed for initial disease (n=25) or recurrence (n= 6). All the 68 involved sites were detected by PET including 5 extra-nodal lesions. Only 43 nodal sites (68%) and one splenic focus were detected by CE. PET changed staging in 9 patients (7 upstaged, 2 downstaged) and radiation fields in 3 patients. These results showed the potential role of PET in the staging of LPHD.

引用

页码：128 / 131

页数：4

共 20 条

[1] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
Cheson, BD
Horning, SJ
Coiffier, B
Shipp, MA
Fisher, RI
Connors, JM
Lister, TA
Vose, J
Grillo-López, A
Hagenbeek, A
Cabanillas, F
Klippensten, D
Hiddemann, W
Castellino, R
Harris, NL
Armitage, JO
Carter, W
Hoppe, R
Canellos, GP
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
[2] Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease
Diehl, V
Sextro, M
Franklin, J
Hansmann, ML
Harris, N
Jaffe, E
Poppema, S
Harris, M
Franssila, K
van Krieken, J
Marafioti, T
Anagnostopoulos, I
Stein, H
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 776 - 783
[3] Diehl V, 1999, HODGKIN'S DISEASE, P563
[4] Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
Ekstrand, BC
Lucas, JB
Horwitz, SM
Fan, Z
Breslin, S
Hoppe, RT
Natkunam, Y
Bartlett, NL
Horning, SJ
[J]. BLOOD, 2003, 101 (11) : 4285 - 4289
[5] Utility of FDG-PET scanning in lymphoma by WHO classification
Elstrom, R
Guan, L
Baker, G
Nakhoda, K
Vergilio, JA
Zhuang, H
Pitsilos, S
Bagg, A
Downs, L
Mehrotra, A
Kim, S
Alavi, A
Schuster, SJ
[J]. BLOOD, 2003, 101 (10) : 3875 - 3876
[6] Harris NL, 1999, SEMIN HEMATOL, V36, P220
[7] HARRIS NL, 1994, BLOOD, V84, P1361
[8] Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake
Hutchings, Martin
Loft, Annika
Hansen, Mads
Ralfkiaer, Elisabeth
Specht, Lena
[J]. HEMATOLOGICAL ONCOLOGY, 2006, 24 (03) : 146 - 150
[9] Hutchings M, 2006, HAEMATOLOGICA, V91, P482
[10] Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)
Jerusalem, G
Beguin, Y
Najjar, F
Hustinx, R
Fassotte, MF
Rigo, P
Fillet, G
[J]. ANNALS OF ONCOLOGY, 2001, 12 (06) : 825 - 830

← 1 2 →